Eton outlines fivefold INCRELEX market opportunity and targets $50M peak adrenal franchise sales amid record Q3 growth
Source: SeekingAlpha
2025-11-06 23:16:53 ET
More on Eton Pharmaceuticals
- Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
- Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold
- Eton Pharmaceuticals Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Eton Pharmaceuticals
- Historical earnings data for Eton Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Eton outlines fivefold INCRELEX market opportunity and targets $50M peak adrenal franchise sales amid record Q3 growth
Eton Pharmaceutcials Inc.
NASDAQ: ETON
ETON Trading
0.52% G/L:
$17.52 Last:
139,977 Volume:
$17.37 Open:
ETON Latest News
March 03, 2026 04:30:00 pm
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 02, 2026 07:27:44 am
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
February 25, 2026 01:47:00 pm
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
February 20, 2026 06:50:00 am
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
ETON Stock Data
$408,699,233
22,518,684
14.05%
24
N/A
Pharmaceuticals
Healthcare
US
Deer Park
